Programmed Application of Transforming Growth Factor β3 and Rac1 Inhibitor NSC23766 Committed Hyaline Cartilage Differentiation of Adipose-Derived Stem Cells for Osteochondral Defect Repair

SHOUAN ZHU, PENGFEI CHEN, YAN WU, SI XIONG, HENG SUN, QINGQING XIA, LIBING SHI, HUANHUAN LIU, HONG WEI OUYANG

Key Words. Adipose-derive stem cells • Rac1 • Osteochondral defect • Hypertrophy

ABSTRACT

Hyaline cartilage differentiation is always the challenge with application of stem cells for joint repair. Transforming growth factors (TGFs) and bone morphogenetic proteins can initiate cartilage differentiation but often lead to hypertrophy and calcification, related to abnormal Rac1 activity. In this study, we developed a strategy of programmed application of TGFβ3 and Rac1 inhibitor NSC23766 to commit the hyaline cartilage differentiation of adipose-derived stem cells (ADSCs) for joint cartilage repair. ADSCs were isolated and cultured in a micromass and pellet culture model to evaluate chondrogenic and hypertrophic differentiation. The function of Rac1 was investigated with constitutively active Rac1 mutant and dominant negative Rac1 mutant. The efficacy of ADSCs with programmed application of TGFβ3 and Rac1 inhibitor for cartilage repair was studied in a rat model of osteochondral defects. The results showed that TGFβ3 promoted ADSCs chondro-lineage differentiation and that NSC23766 prevented ADSC-derived chondrocytes from hypertrophy in vitro. The combination of ADSCs, TGFβ3, and NSC23766 promoted quality osteochondral defect repair in rats with much less chondrocytes hypertrophy and significantly higher International Cartilage Repair Society macroscopic and microscopic scores. The findings have illustrated that programmed application of TGFβ3 and Rac1 inhibitor NSC23766 can commit ADSCs to chondro-lineage differentiation and improve the efficacy of ADSCs for cartilage defect repair. These findings suggest a promising stem cell-based strategy for articular cartilage repair.

INTRODUCTION

Cartilage defect repair is a great clinical challenge owing to its avascularity and low cellular mitotic activity [1]. Conventional treatments have not elicited satisfactory outcomes and usually generate fibrous, rather than hyaline, cartilage [2, 3]. Emerging advances in cell-based articular cartilage tissue engineering provide promising strategies to this unsolved problem. Mesenchymal stem cells (MSCs) isolated from several different tissues, including adipose, bone marrow, and others, offer an attractive cell source for tissue engineering because of their great proliferation and differentiation capabilities [4]. Among them, adipose-derived stem cells (ADSCs) have drawn much attention recently because of their acquisition advantage and useful characteristics comparable to bone marrow stem cells (BMSCs) [5–7]. ADSCs have been intensively studied for the treatment of cartilage lesions since the first demonstration of their chondrogenic potential [8–10]. However, subsequent investigations revealed that ADSCs display a lower chondrogenic potential than BMSCs [11–13], although greater doses of growth factors such as transforming growth factor β (TGFβ) and insulin-like growth factor could overcome this disadvantage [14, 15]. Despite their inferior chondrogenic ability, ADSCs still deserve much more in depth investigation because of their huge advantage regarding acquisition.

Numerous in vitro [16–18] and in vivo [18] studies have shown that MSCs undergo chondrogenesis when supplemented with TGFβ family members. TGFβ3 supplementation can initiate chondro-lineage differentiation. However, TGFβ3 is unable to commit stem cells to stable chondrogenic differentiation. It has often been observed that stem cells treated with TGFβ3 will undergo hypertrophy and calcification [19], because TGFβ3 is also the active signal pathway during endochondral ossification in development [20, 21]. Also, clinical follow-up studies have shown that the newly formed cartilage was associated with osseous overgrowth in 25%–49% of cases [22–24]. Such bony overgrowths, not only have no function, but also impede the integrity of the newly formed tissue with adjacent healthy cartilage.
Rac1 belongs to small GTPases and can interchange between the GTP active form and GDP inactive form. Recent studies from different groups revealed that Rac1 functions as a positive regulator in governing chondrocyte hypertrophy, maturation, and calcification [25–27]. Studies from our laboratory and Long et al. [28] all showed that Rac1 was activated in osteoarthritic (OA) cartilage. We further demonstrated that activated Rac1 resulted in upregulation of hypertrophy related genes such as COLX, MMP13, and ADTAMTS-5 and chondrocyte calcification and that inhibition of Rac1 activity in vivo effectively ameliorated osteoarthritis progression in mice [29]. These findings suggest that inhibition of Rac1 could be an effective method to prevent chondrocyte hypertrophy and calcification.

The principal aim of the present study was to develop a strategy of programmed application of TGF-β3 and Rac1 inhibitor NSC23766 to commit the hyaline cartilage differentiation of ADSCs for joint cartilage repair. Our hypothesis was that TGF-β3 would promote ADSCs chondro-lineage differentiation and that local delivery of NSC23766 would prevent hypertrophy of the chondrocytes. The local delivery system was chitosan microspheres, because they are an inexpensive, biocompatible, biodegradable, and nontoxic natural polymer that enables the controlled release of many drugs [10, 30, 31].

In this study, we evaluated the chondro-lineage differentiation ability of ADSCs in the chondrogenic medium and the inhibitory effect of the Rac1 inhibitor NSC23766 on the hypertrophy of chondrocytes in vitro. From this, in vivo, we evaluated the cartilage reparative potential of ADSCs encapsulated in a biodegradable hydrogel (fibrin) containing TGF-β3. The NSC23766 control released by chitosan microspheres was then intra-articularly administered weekly, and the efficiency of the present strategy for cartilage regeneration was analyzed and evaluated.

**Materials and Methods**

**ADSC Isolation and Characterization**

**Isolation of Rat ADSCs**

Rat ADSCs were isolated from the inguinal area of 6-week-old male Sprague-Dawley rats weighing 160 ± 5 g, as described previously [32]. The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, http://www.invitrogen.com). The fourth to sixth passage cells were used for the experiments.

**Fluorescence-Activated Cell Sorting Analysis**

The cells (1 × 10⁶) were incubated with 1 μg of fluorescein isothiocyanate (FITC)-conjugated mouse anti-rat monoclonal antibodies specific to rat CD29, CD90, CD44, CD45, or FITC-conjugated isotype-matched immunoglobulin G (all from BD, Franklin Lakes, NJ, http://www.bd.com) for 1 hour at 4°C. After washing, the samples were analyzed using an Epics XL flow cytometer (Beckman Coulter, Fullerton, CA, http://www.beckmancoulter.com).

**Multipotent Differentiation**

The multi-differentiation potential of the ADSCs toward osteogenesis, adipogenesis, and chondrogenesis was examined, as described previously [33]. In brief, to promote osteogenic differentiation, the cells were induced at a density of 5 × 10³ cells per centimeter squared by 10 nm β-glycerol phosphate, 0.1 μM dexamethasone, and 50 μg/ml ascorbic acid (all Sigma-Aldrich, St. Louis, MO, http://www.sigmaaldrich.com) for 2 weeks. Positive induction was detected by alizarin red staining. To promote adipogenesis differentiation, the cells were cultured in DMEM supplemented with adipogenic stimulatory supplements (StemCell Technologies, Vancouver, BC, Canada, http://www.stemcell.com) for 2 weeks. Positive induction was detected by oil red staining for lipid vacuoles. To promote chondrogenic differentiation, the cells (10³ cells per centimeter squared) were induced in pellet by culturing in DMEM supplemented with 50 μg/ml ascorbic acid (Sigma-Aldrich), 10 ng/ml TGF-β3 (Millipore, Billerica, MA, http://www.millipore.com), and 10 μM of dexamethasone (Sigma-Aldrich) for 3 weeks. Positive induction was detected by Safranin O staining after 3 weeks.

**Micromass Cultures of ADSCs**

For micromass cultures, the protocol described by De Bari et al. [34] with human periostium-derived cells was used, with some modifications. In brief, confluent monolayer cultures of ADSC lines were released by trypsin-EDTA and resuspended in growth medium at a density of 2.5 × 10⁴ viable cells per milliliter. Micromasses were obtained by pipetting 20 μl of cell suspension into individual wells of 24-well plates. After a 3-hour attachment period without medium, the growth medium was gently added, and the cultures were left to rest for an additional 24 hours. The medium was then changed to serum-free and phenol red-free medium (Gibco-BRL, Gaithersburg, MD, http://www.invitrogen.com) for 24 hours. Differentiation was promoted by 10 ng/ml TGFβ3 supplementation. On day 3 of the culture, fresh differentiation medium was added, and the treatments were performed as described in Results. After 14 days, some micromasses were harvested for Alcian blue (AB) or Safranin O staining. Others were harvested for quantitative reverse transcriptase-polymerase chain reaction (PCR) gene expression analysis of the marker genes for chondrocytes (COLII, COLX, SOX9, MMP13, ADAMTS-5), as described in Real-Time PCR. Positive induction was detected by AB and Safranin O staining.

**Pellet Cultures of ADSCs**

Differentiation of ADSCs was induced in pellet culture by exposure to 10 ng/ml TGF-β3 (Millipore) and 200 mM of ascorbic acid (Sigma-Aldrich) in DMEM-high glucose medium for 4 weeks. The treatments were performed as described in Results. Adherent cell colonies were trypsinized and counted. Aliquots of 2 × 10⁶ cells in 0.5 ml of medium were then centrifuged at 500g for 15–20 min by low-speed centrifugation. Within 24 hours after incubation, the cells had formed an aggregate that did not adhere to the tube walls. The medium was changed every 2 or 3 days, and cell aggregates were obtained at intervals of as long as 21 days. The pellets were harvested for Safranin O staining and immunostaining. Hyaline cartilage marker type II collagen expression was recognized by anti-COLII antibodies (ab116242, Abcam, Cambridge, U.K., http://www.abcam.com). The expression of the hypertrophy markers MMP13, ADAMTS-5, and COLX was recognized by anti-MMP13 antibodies (C0265, Anbobio, San Francisco, CA, http://www.anbobio.com/index.asp), anti-ADAMTS-5 antibodies (ab41037, Abcam), and anti-COLX antibodies (ab58632, Abcam). Data were confirmed in 3 of 4 independent experiments.
Pull-Down Assay for Rac1 Activity

Rac1 activation assays were performed using a commercially available Rac1 activation assay kit (16118, Thermo Pierce, Rockford, IL, http://www.piercenet.com/), in accordance with the manufacturer’s protocol.

Western Blot Analysis

Cellular protein was extracted using RIPA lysis buffer, and the protein concentration was determined using a bichinchonic acid assay kit (Thermo Pierce #23227). The extracted cellular protein was loaded on SDS-polyacrylamide gel electrophoresis denaturing gels. After electrophoresis, the proteins were transferred to a polyvinylidene difluoride membrane and blocked in 5% bovine serum albumin for 1 hour at room temperature. The membrane was incubated overnight at 4°C with anti-Rac1 (Thermo Pierce #16118) or anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Beyotime Institute of Biotechnology, Shanghai, People’s Republic of China) antibody. After washing in Tris-buffered saline with Tween (TBST), horseradish peroxidase secondary antibody was diluted 1:1000 in 5% bovine serum albumin solution and incubated with the membrane for 1 hour at room temperature. Excess secondary antibody was rinsed off the membrane with TBST, and a chemiluminescent signal was generated using Western blot detection reagents (BeyoECL; Beyotime Institute of Biotechnology) according to the manufacturer’s protocol.

Lentivirus Methods

The ADSCs were transfected with lentivirus when 30%–50% confluent at a multiplicity of infection of 200. At 12 hours after infection, more than 95% of the cells were still viable, and the culture medium was then changed. Three days later, all transfected cells were passaged for use in additional experiments.

Real-Time PCR

The mRNA expression levels of genes associated with hypertrophy (MMP13, ADAMTS-5, COLX) or chondrogenesis (COLII and SOX-9) were assessed using real-time PCR. Total cellular RNA was isolated by lysis in TRIzol (Invitrogen, Carlsbad, CA, http://www.invitrogen.com). PCR was performed using Brilliant SYBR Green QPCR Master Mix (TakaRa Bio, Shiga, Japan, http://www.takara-bio.com) with a Light Cycler apparatus (ABI 7900HT). The amplification efficiencies of primer pairs were validated to enable quantitative comparison of gene expression. All primer sequences (Invitrogen) were designed using primer premier 5.0 software. Each qPCR was performed on at least three different experimental samples, and representative results are presented as the target gene expression normalized to the reference gene GAPDH, actin, β2-microglobulin, or hypoxanthine ribosyltransferase. We performed a negative control (without cDNA) for each of the genes we detected, and the negative control did not amplify (cycle threshold >32). Error bars represent ± SD from the mean of the technical replicates. The following primer sequences were used: MMP13: sense 5’-ATGCACTCTTTCTCGGCTTAG-3’, antisense 5’-ATGCATCTGAAGTGTCTGGT-3’; ADAMTS-5: sense 5’-ATCACCACGAGCTGAAG-3’, antisense 5’-AGCAGAGTAGAGCAACAC-3’; COLX: sense 5’-GTGTTTTACCTGGAAACGATACCAA-3’, antisense 5’-ACCTGTTTCCCTACAGTGTG-3’; COLII: sense 5’-GAGAACCTGGATCCCTGGA, antisense 5’-CCTATGACTCCATCTG-3’; and SOX-9: sense 5’-GGAGCTCGAACTGGCTGAA-3’, antisense 5’-GAGGCGAATTGGAGGAGGA-3’.

Osteochondral Defect Model

In the present study, fifteen 12-week-old Sprague-Dawley rats were used and all were treated according to the standard guidelines approved by the Zhejiang University ethics committee (no. ZJU2007105002). Under intramuscular droperidol (0.25 mg/kg), intravenous pentobarbital (20 mg/kg) and general 2% isoflurane (vol/vol) anesthesia, the knee joint was opened using a medial parapatellar approach. The trochlear groove was exposed by lateral dislocation of the patella. A full-thickness cylindrical cartilage defect 2 mm in diameter and 2 mm deep was created in the trochlear groove of the femur using a stainless-steel punch. The defects were managed using one of the five methods listed in Table 1.

Each group consisted of 3 rats. Immediately after surgery, the rats were returned to their individual cages without joint immobilization. A postoperative antibiotic (gentamicin) was administered intramuscularly at 6 mg/kg daily for 3 days. After 6 weeks, the rats were sacrificed.

The specimens were investigated by Safranin O staining and immunostaining. The hyaline cartilage marker COLII expression was recognized by anti-COLII antibodies. The hypertrophy marker (MMP13, ADAMTS-5, and COLX) expression was recognized by the antibodies reported in the Pellet Cultures of ADSCs. The regenerated cartilage was grossly examined using the International Cartilage Repair Society (ICRS) macroscopic score [35], which evaluates the degree of defect repair, integration to the border zone, and the macroscopic appearance. The ICRS Visual Histological Assessment Scale [36] was used to evaluate the quality of the repaired tissue.

Preparation of Chitosan Microspheres

Chitosan microspheres were prepared through the water-in-oil emulsion solvent diffusion method. The chitosan solution (2% wt/vol) was prepared by dissolving chitosan (Shanghai Bio Science and Technology, Shanghai, http://www.sh-bio.com/eweb/index.asp) in 2.5% (vol/vol) acetic acid aqueous solution (Sinopharm Chemical Reagent) at room temperature. The chitosan solution was mixed with inhibitor by stirring overnight with a magnetic stirrer to produce a homogeneous mixture. Then, 5 ml of the mixture was aspirated into a syringe pump and then added drop by drop into the oil phase (24.72 ml) consisting of 14 ml of liquid paraffin (Sinopharm Chemical Reagent), 10 ml of petroleum ether, and 0.72 ml of Span 80 (Sangon Biotech) at a flow rate of 4 ml/hour with continuous stirring at 1500 rpm. A syringe needle with a 0.2-mm internal diameter was used for this process. After the solvent diffusion procedure, the suspension was cross-linked using 25% (vol/vol) glutaraldehyde solution as a cross-linking agent. The addition of the cross-linker was performed three times at intervals of 15 minutes, with the following volumes of glutaraldehyde: 0.64, 0.64, and 0.32 ml. Subsequently, the suspension was stirred at room temperature for cross-linking and then centrifuged at 3000 rpm for 5 minutes, followed by discarding the supernatant fluid. The microspheres were then washed three times with petroleum ether, two times with methanol, one time with acetone, one time with isopropyl alcohol (all from Sinopharm Chemical Reagent), one time with ethanol, and three times with distilled water. After washing, the microspheres were collected by lyophilizing with a freeze dryer to remove residual water.
Table 1. Description of methods used to manage the defects

| Group | Description |
|-------|-------------|
| 1     | Defect left untreated |
| 2     | Defect filled with 0.1 ml of fibrin gel only |
| 3     | Defect filled with $1 \times 10^6$ ADSCs suspended in 0.1 ml of fibrin gel |
| 4     | Defect filled with $1 \times 10^6$ ADSCs suspended in 0.1 ml of fibrin gel plus, from 7 days after surgery, chitosan microspheres were injected into the rat joints once each week |
| 5     | Defect filled with $1 \times 10^6$ ADSCs suspended in 0.1 ml of fibrin gel plus from 7 days after surgery, chitosan microspheres releasing NSC23766 were injected into the rat joints once each week |

Abbreviation: ADSCs, adipose-derived stem cells.

For the control group, pure chitosan microspheres were also prepared by directly dropping chitosan solution into the oil phase under the same conditions.

Statistical Analysis

All quantitative data are presented as the mean ± SD. Nonparametric statistical tests were performed to assess statistically significant differences in the data between groups. Values of $p < .05$ were considered statistically significant. The significance level is presented as either $p < .05$ or $p < .01$.

RESULTS

Immunophenotypic Characterization and Multilineage Differentiation Ability of ADSCs

To verify that the stem cell phenotypes were maintained in the subcultures of ADSCs, the mesenchymal characteristics were evaluated using the positive MSC markers, CD90, CD29, and CD44, and the negative MSC marker CD45. The MSC markers CD90, CD29, and CD44 were observed in more than 90% of the cells (Fig. 1A), and the MSC negative marker CD45 was observed in less than 10% of the cells (Fig. 1B). An osteogenic differentiation assay confirmed that most of the cells had mineralized calcium deposits after 2 weeks of induction, as shown by alizarin red staining (Fig. 1C). Oil red O and Safranin O staining demonstrated that the cells after induction were able to differentiate into adipogenic and chondrogenic lineages, respectively (Fig. 1C). Taken together, our results suggest that we successfully isolated and maintained ADSCs.

Inhibition of Rac1 Activity in ADSCs Reduced Chondrocyte Hypertrophy-Like Changes Without Affecting Chondrogenesis In Vitro

We have previously reported that activation of Rac1 in chondrocytes promotes chondrocyte hypertrophy and calcification. In this study, we checked the role of Rac1 in ADSC chondrogenic differentiation. ADSCs were infected with constitutively active Rac1 mutant (Ca-Rac1) and dominant negative Rac1 (DN-Rac1) virus (Fig. 2A). In a micromass culture model, CA-Rac1 or DN-Rac1 expression did not affect the chondrogenic capability of the ADSCs, demonstrated by Safranin O staining (Fig. 2B). In another chondrogenic model of pellet culture, TGFβ3 unambiguously induced expression of chondrocyte hypertrophy, and calcification-related genes, including ADAMTS-5, MMP13, and COLX (Fig. 2C), could, to a great extent, be reduced by DN-Rac1. These results indicate that TGFβ3 promotes chondrogenic differentiation of ADSCs, and inhibition of Rac1 activity prevents ADSCs from undergoing hypertrophy.

TGFβ3 Promoted ADSC Chondrogenic Differentiation and Rac1 Inhibitor NSC23766 Inhibited Hypertrophy In Vitro

We also studied the collaborative roles of TGFβ3 and Rac1 inhibitor NSC23766 on ADSC chondrogenic differentiation. ADSCs were cultured in high density using a micromass culture model. Real-time quantitative polymerase chain reaction (qPCR) was performed for selected chondrogenic (type II collagen and Sox9) and hypertrophic (MMP13, COLX, and ADAMTS-5) markers. Supplementation with TGFβ3 greatly promoted chondrogenesis, and the addition of the Rac1 inhibitor NSC23766 did not affect the chondrogenic differentiation of ADSCs, demonstrated by both Alcian blue and Safranin O staining (Fig. 3A) and the qPCR results for COLII and Sox9 (Fig. 3B). Supplementation with NSC23766 significantly suppressed TGFβ3-induced hypertrophy gene upregulation (Fig. 3C). Testing of several other reference genes demonstrated that the qPCR is robust (supplemental online Fig. 1). We also tested the effect of NSC23766 in another chondrogenic model of pellet culture. Histological staining suggested NSC23766 had no effect on chondrogenic differentiation of ADSCs; nonetheless, inhibition of Rac1, to a great extent, decreased expression of the hypertrophic markers such as MMP13, ADAMTS-5, and COLX (Fig. 3D).

In the next step, we tested the feasibility of promoting cartilage repair using these two reagents. We prepared fibrin gel encapsulated ADSCs cultured in medium supplemented with TGFβ3 or TGFβ3 plus NSC23766 for 21 days. COLII expression, a characteristic of differentiated chondrocytes, could be detected in the cells with TGFβ3 but not in the control group. Consistently, the Safranin O-positive proteoglycan showed remarkable increases in the TGFβ3 treated group compared with the control group (Fig. 3E). Also, inhibition of Rac1 decreased the expression of hypertrophic markers such as ADAMTS-5 and COLX (Fig. 3E). These results encouraged us to further apply this strategy to cartilage repair and regeneration.

Programmed Addition of TGFβ3 and NSC23766 Promoted ADSCs for Cartilage Repair In Vivo

Osteochondral defects were created in the patellar groove of rat distal femurs, and ADSCs encapsulated in fibrin gel supplemented with or without TGFβ3 were implanted in the defects. From 7 days after surgery, chitosan microspheres containing NSC23766 were injected into the rat joints once a week; the whole joints were collected 6 weeks after surgery (Fig. 4A). The chitosan microspheres were spherical, with a mean size of around 100 μm and had a smooth surface without cracks or wrinkles, demonstrated by scanning electron micrographs (Fig. 4B). The control release ability of chitosan microspheres was determined by measuring the optical density of the extracts at 360 nm (which is specific for NSC23766). NSC23766 was released from the microspheres in a biphasic fashion, characterized by a fast release phase on the initial day 1, followed by slower release on the remaining days (Fig. 4C). In three groups (F+ADSCs [10% fetal bovine serum plus ADSCs], F+ADSCs+T [10% fetal bovine serum plus ADSCs plus TGFβ2], and F+ADSCs+T+NSC [10% fetal bovine serum plus ADSCs plus TGFβ2 plus NSC23766]), the defect had become firm and...
smooth after 6 weeks. In contrast, a soft and friable tissue was present in groups D (Defect) and F (Fibrin), demonstrated by macroscopic assessment (Fig. 4D). A Rac1 pull-down assay demonstrated that Rac1 activity had been significantly inhibited by NSC23766 (Fig. 4E). The ICRS macroscopic score was highest in groups F+ADSCs+T+NSC (10.0) and F+ADSCs+T (9.8), followed by group F+ADSCs (6.2) and group F (4.3). These results suggest that ADSCs encapsulated in fibrin gel supplemented with TGFβ3 can greatly promote the repair of osteochondral defects.

**Histological Assessment of Repair**

Histological analysis at 6 weeks after surgery demonstrated a smooth articular surface with restoration of hyaline
cartilage-like tissue stained with Safranin O in groups F+ADSCs+T+NSC and F+ADSCs+T. The defects in group F+ADSCs had incomplete healing with hyaline cartilage-like tissue limited to a few area of the defects, with most of the defect area filled with fibrous tissue (Fig. 5A). In group F, the defects were almost completely filled with fibrous tissue with little Safranin O staining (Fig. 5A). Group D displayed disruption of subchondral bone and a thin layer of fibrous tissue (Fig. 5A). Also, the immunohistochemical results demonstrated that TGFβ3 stimulated hyaline cartilage marker type II collagen expression, and the addition of

Figure 3. Transforming growth factor β3 (TGFβ3) promotes adipose-derived stem cell (ADSC) chondrogenic differentiation and NSC23766 inhibits hypertrophy in vitro. (A, B): Micromass culture model demonstrated TGFβ3-induced chondrogenesis. The addition of the Rac1 inhibitor did not impede chondrogenesis (A) or COLII and Sox9 expression (B). (C): Addition of Rac1 inhibitor NSC23766 decreased TGFβ3-induced MMP13, ADAMTS-5, and COLII expression. (D): Pellet culture model also confirmed that supplementation with NSC23766 prevented hypertrophy without affecting the chondrogenesis of ADSCs, demonstrated by immunostaining of COLII, COLX, MMP13, and ADAMTS-5. Scale bars = 100 μm. (E): Safranin O staining of ADSCs treated with TGFβ3 or TGFβ3+NSC23766 and the detection of COLII, COLX, and ADAMTS-5 by immunostaining. Scale bars = 1 mm or 100 μm. Abbreviations: AB, Alcian blue staining; ADSCs, adipose-derived stem cells; CLT, control; HE, hematoxylin and eosin stain; NSC, NSC23766; SO, Safranin O; T, transforming growth factor β3.
NSC23766 did not interfere with this effect (Fig. 5A). The ICRS Visual Histological Assessment Scale showed that groups F+ADSCs+T+NSC and F+ADSCs+T had much better results than groups F+ADSCs and F (Fig. 5B). These results suggest that supplementation with TGFβ3 could to a large extent promote ADSC chondrogenic differentiation and lead to better articular cartilage repair.

**Effect of Rac1 Inhibitor NSC23766 on TGFβ3 Induced Chondrocyte Hypertrophy In Vivo**

Because TGFβ3 supplementation promotes chondrogenesis and causes undesired events such as hypertrophy and calcification, we checked whether NSC23766 could ameliorate these side effects using an immunohistochemical assay for hypertrophy marker (MMP13, ADAMTS-5, and COLX) expression. We found many fewer chondrocytes in group F+ADSCs+T+NSC cartilage expressing MMP13, ADAMTS-5, and COLX than in group F+ADSCs+T (Fig. 6A, 6C, 6E). In addition, MMP13- and COLX-positive chondrocytes were limited to a deep area in group F+ADSCs+T+NSC, and in group F+ADSCs+T, the MMP13- and COLX-positive chondrocytes were distributed over the whole thickness of the cartilage (Fig. 6A, 6C). The quantitative results showed that controlled release of NSC23766 in rat joints significantly decreased the percentage of MMP13-, COLX-, and ADAMTS-5-positive chondrocytes (Fig. 6B, 6D, 6F). These results demonstrated that controlled release of NSC23766 by chitosan microspheres greatly ameliorated the TGFβ3-induced chondrocyte hypertrophy.

**DISCUSSION**

In this study, we developed a new stem cell-based strategy for cartilage defect repair in which a chondro-lineage differentiation activator (TGFβ3) and chondrocyte hypertrophy inhibitor (Rac1 inhibitor NSC23766) were applied. Our study had several major findings. First, genetic modulation of Rac1 activity by DN-Rac1 suppressed cell hypertrophy without affecting the chondrogenic ability of the ADSCs. Second, programmed application of TGFβ3 and the Rac1 inhibitor NSC23766 committed the ADSCs to chondro-lineage differentiation without hypertrophy. Finally, the strategy of programmed application of TGFβ3 and NSC23766 improved the efficacy of ADSCs for cartilage repair.
healing in the rat knee joint. These data collectively suggest that programmed application of TGFβ3 and Rac1 inhibitor NSC23766 can commit ADSCs to chondro-lineage differentiation and improve the efficacy of ADSCs for cartilage defect repair.

The present study has shown that supplementation of TGFβ3 greatly promotes ADSC chondrogenic differentiation. ADSCs could be an alternative autologous cell source for cartilage regeneration that is easier to obtain, has lower donor-site morbidity, and is available in larger numbers than stem cells harvested using bone marrow aspiration [37–39]. Generally, in vitro chondrogenic differentiation of ADSCs is induced by culturing ADSCs in a pellet with supplementation of TGFβ3 [40]. However, many issues still need to be considered, such as whether during induction of chondrogenesis in vitro, cells adopt natural differentiation stages, and whether they can form ectopic stable cartilage that is resistant to hypertrophy and calcification in vivo [41].

Previously, we reported that Rac1 was aberrantly activated in OA chondrocytes and inhibition of Rac1 activity in vivo protected cartilage from deterioration by reducing chondrocyte hypertrophy [29]. In this study, we used the Rac1 inhibitor NSC23766 to facilitate the efficiency of TGFβ3-induced ADSC chondrogenesis by suppressing chondrocytes from undergoing hypertrophy and calcification.

For cartilage defects, many surgical treatments involving microfracture, joint debridement and drilling, autologous chondrocyte/bone marrow mesenchymal stem cell implantation have been successfully used in clinics [42]. However, these therapeutic methods mainly focused on the supply of cells and ignored the hypertrophy and calcification caused by the cytokines. In our study, we developed a strategy of programmed application of TGFβ3 and the Rac1 inhibitor NSC23766 to commit the hyaline cartilage differentiation of ADSCs for joint cartilage repair.

Characterized by biocompatibility, nontoxicity, a lack of allergenicity, and biodegradability, chitosan microspheres are an attractive biopolymer for drug delivery systems in a controlled and/or sustained manner and can be successfully targeted for site-specific drug delivery [32, 43]. Hyaluronic acid (HA) is a sterile, viscoelastic, nonpyogenic glycosaminoglycan that is indicated as a medical device for the treatment of pain in patients with knee injuries [44–46]. In this study, HA-containing chitosan microspheres encapsulating the Rac1 inhibitor NSC23766 were injected into rat joints for sustained release to lubricate the joints and remit the pain. However, the controlled release system used in this study could only guarantee sustained release for 3 days owing to the relative inhomogeneous and large size of the chitosan microspheres. Additional work will aim to develop a more efficient delivery system by controlling the size and homogeneity of the biomaterial spheres to maintain the drug concentration in the OA joint.

**CONCLUSION**

In this study, we have shown that programmed application of TGFβ3 and Rac1 inhibitor NSC23766 can commit ADSCs to chondro-lineage differentiation and improve the efficacy of ADSCs for cartilage defect repair by slowing the progression to hypertrophy. Our findings have also provided additional support for the importance of Rac1 as a therapeutic target for cartilage degeneration.
This work was supported by the National Program on Key Basic Research project (Grant 2012CB966604), the National Natural Science Fund (Grants 81125014, 81101356, 81201395, and 31000436), Zhejiang Province Public Welfare Fund (Grant 2012C3112), Zhejiang Provincial Natural Science Foundation of China (Grant LY13C100001), and Postdoctoral Foundation of China (Grant 2013M531465), and was sponsored by the Regenerative Medicine in Innovative Medical Subjects of Zhejiang Province and Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents. We also thank the care facilities of Zhejiang University School of Medicine for technical assistance.

ACKNOWLEDGMENTS

S.Z. and P.C.: in vitro cell culture and histological assessment; Y.W.: osteochondral defect surgery; S.X. chitosan microsphere preparation; H.S., Q.X., and L.S.: fluorescence-activated cell sorting analysis and Western blotting; H.L. and H.W.O. manuscript writing.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

The authors indicate no potential conflicts of interest.

REFERENCES

1 Hunziker EB. Articular cartilage repair: Basic science and clinical progress: A review of the current status and prospects. Osteoarthritis Cartilage 2002;10:432–463.
2 Camp CL, Stuart MJ, Krych AJ. Current concepts of articular cartilage restoration techniques in the knee. Sports Health 2014;6:265–273.
3 Rodriguez-Merchan EC. Regeneration of articular cartilage of the knee. Rheumatol Int 2013;33:837–845.
4 Caplan AI. Review: Mesenchymal stem cells: Cell-based reconstructive therapy in orthopedics. Tissue Eng 2005;11:1198–1211.
5 Zuk PA, Zhu M, Asahijan P et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002;13:4279–4295.
6 Rodríguez AM, Elabd C, Amyt EZ et al. The human adipose tissue is a source of multipotent stem cells. Biochimie 2005;87:125–128.
7 Zuk PA, Zhu M, Mizuno H et al. Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng 2001;7:211–228.
8 Erickson GR, Gimble JM, Franklin DM et al. Chondrogenic potential of adipose tissue-derived stem cells in vitro and in vivo. Biochem Biophys Res Commun 2002;290:763–769.
9 Masuoka K, Asazuma T, Hattori H et al. Tissue engineering of articular cartilage with autologous cultured adipose tissue-derived stem cells using atelocollagen honeycomb-shaped scaffold with a membrane sealing in rabbits. J Biomed Mater Res B Appl Biomater 2006;79:25–34.
10 Dragoo JL, Carlson G, McCormick F et al. Healing full-thickness cartilage defects using adipose-derived stem cells. Tissue Eng 2007;13:1615–1621.
11 Sakaguchi Y, Sekiya I, Yagishita K et al. Comparison of human stem cells derived from various mesenchymal tissues: Superiority of synovium as a cell source. Arthritis Rheum 2005;52:2521–2529.
12 Im GI, Shin YW, Lee KB. Do adipose tissue-derived mesenchymal stem cells have the same osteogenic and chondrogenic potential as bone marrow-derived cells? Osteoarthritis Cartilage 2005;13:845–853.
13 Afizah H, Yang Z, Hui JH et al. A comparison between the chondrogenic potential of human bone marrow stem cells (BMSCs) and adipose-derived stem cells (ADSCs) taken...
from the same donors. Tissue Eng 2007;13: 659–666.
14 Im GI, Lee JH. Repair of osteochondral defects with adipose stem cells and a dual growth factor-releasing scaffold in rabbits. J Biomed Mater Res B Appl Biomater 2010;92: 552–560.
15 Kim HJ, Im GI. Chondrogenic differentiation of adipose tissue-derived mesenchymal stem cells: Greater doses of growth factor are necessary. J Orthop Res 2009;27:612–619.
16 Huang AH, Farrell MJ, Mauck RL. Mechanics and mechanobiology of mesenchymal stem cell-based engineered cartilage. J Biomech 2010;43:128–136.
17 Kim M, Erickson IE, Choudhury M et al. Transient exposure to TGF-β3 improves the functional chondrogenesis of MSC-laden hyaluronic acid hydrogels. J Mech Behav Biomed Mater 2012;11:92–101.
18 Ronzière MC, Perrier E, Malein-Gerin F et al. Chondrogenic potential of bone marrow- and adipose tissue-derived adult human mesenchymal stem cells. Biomed Mater Eng 2010; 20:145–158.
19 Barry F, Boynton RE, Liu B et al. Chondrogenic differentiation of mesenchymal stem cells from bone marrow: Differentiation-dependent gene expression of matrix components. Exp Cell Res 2001;268:189–200.
20 Kronenberg HM. Developmental regulation of the growth plate. Nature 2003;423: 1919–20.
21 Tamamura Y, Otani T, Kanatani N et al. Developmental regulation of Wnt/beta-catenin signals is required for growth plate assembly, cartilage integrity, and endochondral ossification. J Biol Chem 2005;280:19185–19195.
22 Mitchofer K, Williams RJ III., Warren RF et al. The microfracture technique for the treatment of articular cartilage lesions in the knee: A prospective cohort study. J Bone Joint Surg Am 2005;87:1911–1920.
23 Kreuz PC, Steinwachs MR, Erggelet C et al. Results after microfracture of full-thickness chondral defects in different compartments in the knee. Osteoarthritis Cartilage 2006;14:1119–1125.
24 Brown WE, Potter HG, Marx RG et al. Magnetic resonance imaging appearance of cartilage repair in the knee. Clin Orthop Relat Res 2004;422:214–213.
25 Woods A, Wang G, Dupuis H et al. Rac1 signaling stimulates N-cadherin expression, mesenchymal condensation, and chondrogenesis. J Biol Chem 2007;282:23500–23508.
26 Wang G, Beier F. Rac1/Cdc42 and RhoA GTPases antagonistically regulate chondrocyte proliferation, hypertrophy, and apoptosis. J Bone Miner Res 2005;20:1022–1031.
27 Wang G, Woods A, Agoston H et al. Genetic ablation of Rac1 in cartilage results in chondrodysplasia. Dev Biol 2007;306:612–623.
28 Long DL, Willey JS, Loeser RF. Rac1 is required for matrix metalloproteinase-13 production by chondrocytes in response to fibroentin fragments. Arthritis Rheum 2013;65:1561–1568.
29 Zhu S, Lu P, Liu H et al. Inhibition of Rac1 activity by controlled release of NSC23766 from chitosan microspheres effectively ameliorates osteoarthritis development in vivo. Ann Rheum Dis 2013 [Epub ahead of print].
30 Alpar HO, Somavaranapu S, Atuah KN et al. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev 2005;57:411–430.
31 Illum L, Watts P, Fisher AN et al. Intranasal delivery. Drug Deliv 2004;11:113–122.
32 Jain SK, Chourasia MK, Jain AK et al. Development and characterization of mucoadhesive microparticles for nasal delivery Drug Deliv 2005;11:113–122.
33 Lee JM, Im GI. SOX trio-co-transduced adipose stem cells in fibrin gel to enhance cartilage repair and delay the progression of osteoarthritis in the rat. Biomaterials 2012;33:2016–2024.
34 Chen X, Song XH, Yin Z et al. Stepwise differentiation of human embryonic stem cells promotes tendon regeneration by secreting fetal tendon matrix and differentiation factors. Stem Cells 2009;27:1276–1287.
35 De Bari C, Dell Accio F, Luyten FP. Human periosteum-derived cells maintain phenotypic stability and chondrogenic potential throughout expansion regardless of donor age. Arthritis Rheum 2001;44:85–95.
36 van den Borne MP, Rajmakers NJ, Vanlauwe J et al. International Cartilage Repair Society (ICRS) and Oswestry macroscopic cartilage evaluation scores validated for use in autologous chondrocyte implantation (ACI) and microfracture. Osteoarthritis Cartilage 2007;15:1397–1402.
37 Mainil-Varlet P, Aigner T, Britberg M et al. Histological assessment of cartilage repair: A report by the Histology Endpoint Committee of the International Cartilage Repair Society (ICRS). J Bone Joint Surg Am 2003;85-A(suppl 2):45–57.
38 Yoon HH, Bhang SH, Shin JY et al. Enhanced cartilage formation via three-dimensional cell engineering of human adipose-derived stem cells. Tissue Eng Part A 2012;18:1949–1956.
39 Veronesi F, Maglio M, Tschon M et al. Adipose-derived mesenchymal stem cells for cartilage tissue engineering: State-of-the-art in vivo studies. J Biomed Mater Res A 2014;102:2448–2466.
40 Technau A, Froelich K, Hagen R et al. Adipose tissue-derived stem cells show both immunogenic and immunosuppressive properties after chondrogenic differentiation. Cytotherapy 2011;13:310–317.
41 Pelttari K, Winter A, Steck E et al. Premature induction of hypertrophy during in vitro chondrogenesis of human mesenchymal stem cells correlates with calcification and vascular invasion after ectopic transplantation in SCID mice. Arthritis Rheum 2006;54:3254–3266.
42 Ahmed TA, Hincke MT. Strategies for articular cartilage lesion repair and functional restoration. Tissue Eng Part B Rev 2010;16:305–329.
43 Kang ML, Kang SG, Jiang HL et al. In vivo induction of mucosal immune responses by intranasal administration of chitosan microspheres containing Bordetella bronchiseptica DNT. Eur J Pharm Biopharm 006;63:215–220.
44 Curran MP. Hyaluronic acid (Supartz®): A review of its use in osteoarthritis of the knee. Drugs Aging 2010;27:925–941.
45 Munteanu SE, Zammitt GV, Menz HB et al. Effectiveness of intra-articular hyaluronan (Synvisc, hylan G-F 20) for the treatment of first metatarsophalangeal joint osteoarthritis: A randomised placebo-controlled trial. Ann Rheum Dis 2011;70:1838–1841.
46 Yatabe T, Mochizuki S, Takiwa M et al. Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic chondrocytes. Ann Rheum Dis 2009;68:1051–1058.